MAIA Biotechnology annual stock-based compensation
2021
2022
2023
2024
2025
MAIA Biotechnology Stock-Based Compensation Growth & History (MAIA)
MAIA Biotechnology's stock-based compensation was $2.6M for fiscal 2025.
View full MAIA Biotechnology company overviewMAIA Biotechnology annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.6M | $718,908 | +37.59% |
| 2024 | 2024-12-31 | $1.9M | −$1.2M | −38.08% |
| 2023 | 2023-12-31 | $3.1M | $769,877 | +33.19% |
| 2022 | 2022-12-31 | $2.3M | −$403,466 | −14.82% |
| 2021 | 2021-12-31 | $2.7M | — | — |
MAIA Biotechnology quarterly stock-based compensation
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $723,915 | −$78,569 | −9.79% |
| Q1 2026 | 2026-03-31 | $650,024 | $278,552 | +74.99% |
| Q4 2025 | 2025-12-31 | $810,796 | $117,353 | +16.92% |
| Q3 2025 | 2025-09-30 | $646,900 | $191,512 | +42.05% |
| Q2 2025 | 2025-06-30 | $802,484 | $388,536 | +93.86% |
| Q1 2025 | 2025-03-31 | $371,472 | $21,507 | +6.15% |
| Q4 2024 | 2024-12-31 | $693,443 | −$668,492 | −49.08% |
| Q3 2024 | 2024-09-30 | $455,388 | −$115,528 | −20.24% |
| Q2 2024 | 2024-06-30 | $413,948 | −$204,983 | −33.12% |
| Q1 2024 | 2024-03-31 | $349,965 | −$187,557 | −34.89% |
| Q4 2023 | 2023-12-31 | $1.4M | $873,044 | +178.58% |
| Q3 2023 | 2023-09-30 | $570,916 | $38,478 | +7.23% |
| Q2 2023 | 2023-06-30 | $618,931 | $34,163 | +5.84% |
| Q1 2023 | 2023-03-31 | $537,522 | −$175,808 | −24.65% |
| Q4 2022 | 2022-12-31 | $488,891 | — | — |
| Q3 2022 | 2022-09-30 | $532,438 | −$246,106 | −31.61% |
| Q2 2022 | 2022-06-30 | $584,768 | −$192,364 | −24.75% |
| Q1 2022 | 2022-03-31 | $713,330 | — | — |
| Q3 2021 | 2021-09-30 | $778,544 | — | — |
| Q2 2021 | 2021-06-30 | $777,132 | — | — |
MAIA Biotechnology stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, MAIA Biotechnology's stock-based compensation decreased from $2.7M to $2.6M, a change of −$91,241. The latest reported quarter, Q2 2026, shows $723,915.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MAIA Biotechnology source filings ↗